- P-ISSN 1010-0695
- E-ISSN 2288-3339
- Apply for Authority
- P-ISSN1010-0695
- E-ISSN2288-3339
Article Detail
Home > Article Detail
Neuroprotective Effect of PD-1 Extract in MPTP-lesioned Mouse Model of Parkinson’s Disease
Journal of Korean Medicine / Journal of Korean Medicine, (P)1010-0695; (E)2288-3339
2009, v.30 no.4, pp.79-92
&
(2009). Neuroprotective Effect of PD-1 Extract in MPTP-lesioned Mouse Model of Parkinson’s Disease. Journal of Korean Medicine, 30(4), 79-92.
- Downloaded
- Viewed
Abstract
Objectives:The aim of the present study was to explore the neuroprotective effect and the possible mechanism of the PD-1 extracts on 1-methyl-4-phenyl-1,2,3,6-tetrahydrophridine (MPTP)-lesioned C57BL/6 mouse model of Parkinson’s disease (PD). Methods:The mice were supplemented (or not) with 50 or 100 mg/kg/day of PD-1 for 2 weeks, after which MPTP was injected intraperitoneally. We observed that daily administration of PD-1 prevented MPTP-induced depletion of striatal DA, and maintained striatal and nigral tyrosine hydroxylase (TH) protein levels. Results:Our results demonstrated that mice treated with PD-1 prior to MPTP administration showed more abundant TH-immunopositive (TH-ir) fibers and neurons than mice given only MPTP, indicating that PD-1 protects dopaminergic striatal fibers and nigral neurons from MPTP insults. Possible neuroprotective effect of PD-1 was further studied by the detection of antiapoptotic protein (bcl-2) and proapoptotic protein (Bax). In this assay, MPTP elevated the Bax protein and decreased the bcl-2 protein, while these expressions were prevented by PD-1 pre-treatment. Conclusions:The present results suggest that PD-1 is able to protect dopaminergic neurons from MPTP-induced neuronal injury with anti-apoptotic activity being one of the possible mechanisms.
- keywords
- PD-1, Parkinson disease, 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydrophridine
Reference
1
김은선, 박동운, 이종은. 뇌질환 치료제 (Ⅰ), 산업시장분석. 한국과학기술 정보연구원; 2006, p. 25-55.
2
서무규. 成人病 老人病學. 서울: 고려의학; 1992, p. 37-49, 77-83, 107-22, 137-9, 142-9.
3
Jenner P, Olanow C. Understanding cell death in Parkinson’s disease. Ann Neurol. 1998;3:S72-S84.
4
Camins A, Pallas M, Silvestre JS. Apoptotic mechanisms involved in neurodegenerative diseases: experimental and therapeutic approaches. Methods Find Exp Clin Pharmacol. 2008;30(1):43-65.
5
Mancuso C, Scapagini G, Currò D, Giuffrida Stella AM, De Marco C, Butterfield DA et al. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front Biosci. 2007;12:1107-23.
6
Zhao M, Momma S, Delfani K, Carlen M, Cassidy RM, Johansson CB et al. Evidence for neurogenesis in the adult mammalian substantia nigra. Proc Natl Acad Sci USA. 2003;100(13):7925-30.
7
Rock RB, Peterson PK. Microglia as a pharmacological target in infectious and inflammatory diseases of the brain. J Neuroimmune Pharmacol. 2006;1(2):117-26.
8
Wilms H, Zecca L, Rosenstiel P, Sievers J, Deuschl G, Lucius R. Inflammation in Parkinson’s diseases and other neurodegenerative diseases: cause and therapeutic implications. Curr Pharm Des. 2007;13(18):1925-8.
9
Fox SH, Chuang R, Brotchie JM. Parkinson’s disease-opportunities for novel therapeutics to reduce the problems of levodopa therapy. Prog Brain Res. 2008;172:479-94.
10
Zhang X, Andren PE, Greengard P, Svenningsson P. Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism. Proc Natl Acad Sci USA. 2008;105(6):2163-8.
11
Yang YL, Meng CH, Ding JH, He HR, Ellsworth K, Wu J et al. Iptakalim hydrochloride protects cells against neurotoxin-induced glutamate transporter dysfunction in vitro and in vivo models. Brain Res. 2005;1049:80-8.
12
Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci. 2005;28:57-87.
13
Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4- phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 1985;36(26):2503-8.
14
Liu HQ, Zhang WY, Luo XT, Ye Y, Zhu XZ. Paeoniflorin attenuates neuro- inflammation and dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease by activation of adenosine A1 receptor. Br J Pharmacol. 2006;148:314-25.
15
Eslamboli A. Marmoset monkey models of Parkinson’s disease: which model, when and why? Brain Res Bull. 2005;68(3):140-9.
16
Smeyne RJ, Jackson-Lewis V. The MPTP model of Parkinson’s disease. Brain Res Mol Brain Res. 2005;134(1):57-66.
17
Liu HQ, Zhang WY, Luo XT, Ye Y, Zhu XZ. Paeoniflorin attenuates neuro- inflammation and dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease by activation of adenosine A1 receptor. Br J Pharmacol. 2006;148:314-25.
18
Van Kampen J, Robertson H, Hagg T, Drobitch R. Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson’s disease. Exp Neurol. 2003;184(1):521-9.
19
Cao F, Sun S, Tong ET. Experimental study on inhibition of neuronal toxical effect of levodopa by ginkgo biloba extract on Parkinson disease in rats. J Huazhong Univ Sci Technolog Med Sci. 2003;23(2):151-3.
20
Li FQ, Cheng XX, Liang XB, Wang XH, Xue B, He QH et al. Neurotrophic and neuroprotective effects of tripchlorolide, an extract of Chinese herb Tripterygium wilfordii Hook F, on dopaminergic neurons. Exp Neurol. 2003;179(1):28-37.
21
Ramassamy C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol. 2006;545(1):51-64.
22
Van Kampen J, Robertson H, Hagg T, Drobitch R. Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson’s disease. Exp Neurol. 2003;184(1):521-9.
23
Chen LW, Wang YQ, Wei LC, Shi M, Chan YS. Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson’s disease. CNS Neurol Disord Drug Targets. 2007(4):273-81.
24
Li Q, Zhao D, Bezard E. Traditional Chinese medicine for Parkinson’s disease: a review of Chinese literature. Behav Pharmacol. 2006 Sep;17(5-6):403-10.
25
Zhou J, Tang XC. Huperzine A attenuates apoptosis and mitochondria-dependent caspase-3 in rat cortical neurons. FEBS Lett. 2002;526:21-5.
26
Grammatopoulos TN, Morris K, Bachar C, Andres MS, Weyhenmeyer RJ. Angiotensin II attenuates chemical hypoxia-induced caspase-3 activation in primary cortical neuronal cultures. Brain Res Bull. 2004;62:297-303.
27
Chang SH, Phelps PC, Berezesberger IK, Ebersberger ML Jr, Trump BF. Studies on the mechanisms and kinetics of apoptosis-induced by microinjection of cytochrome c in rat kidney tubule epithelial cells(NRK-52E). Am J Pathol. 2000;156:637-49.
28
Schapira AH. Progress in neuroprotection in Parkinson’s disease. Eur J Neurol. 2008;15:5-13.
29
전국한의과대학 공동교수편집위원회. 本草學. 서울: 永林社; 2007, p. 154-5, 163-4, 171-2, 184-5, 205-6, 315-6, 503-4, 540-4, 583-6, 634-5, 644-5.
30
Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, Schwarting RK. MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet. 2000;30(3):171-82.
31
Stack EC, Ferro JL, Kim J, Del Signore SJ, Goodrich S, Matson S et al. Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson’s disease. Biochim Biophys Acta. 2008;1782(3): 151-62.
32
Kaul S, Kanthasamy A, Kitazawa M, Anantharam V, Kanthasamy AG. Caspase-3 dependent proteolytic activation of protein kinase C delta mediates and regulates 1- methyl-4-phenylpyridinium(MPP+)-induced apoptotic cell death in dopaminergic cells: relevance to oxidative stress in dopaminergic degeneration. Eur J Neurosci. 2003;18(6):1387-401.
33
Yuan J, Lipinski M, Degterev A. Diversity in the mechanisms of neuronal cell death. Neuron. 2003;40:401-413.
34
Harris CA, Johnson EM, Jr. BH3-only bcl-2 family members are coordinately regulated by the JNK pathway and require bax to induce apoptosis in neurons. J Biol Chem. 2001;37754-60.
35
Gross A, McDonnell JM, Korsmeyer SJ. bcl-2 family members and the mitochondria in apoptosis. Genes Dev. 1999;13:1899-911.
- Downloaded
- Viewed
- 0KCI Citations
- 0WOS Citations
Other articles from this issue
- Studies on the Anti-cancer Activity of Chaga Mushroom Extract
- The Effect of Trans-cinnamaldehyde on the Gene Expression of Lipopolysaccharide-stimulated BV-2 Cells Using Microarray Analysis
- Need for Development of Oriental Medicine-derived Systemic Treatments against Chronic Fatigue-associated Symptoms
- Consideration on the Paste Preparation Based on Entries from the Annals of the Chosun Dynasty
- Collecting Method and Implementation of Search Management System for R&D Projects in Korean Medicine Field
- Study on the Sasang Constitutional Difference between Married Men & Women
- A Study on Korean Oriental Medical Doctors’ Use of Uninsured Herbal Extracts and How to Promote the Insurance Coverage of Such Herbal Extracts
- Neuroprotective Effect of PD-1 Extract in MPTP-lesioned Mouse Model of Parkinson’s Disease
- Effects of the Houttuyniae Herba Extract on the Membranous Nephropathy induced by Cationic Bovine Serum Albumin in Mice
- Concentration of Heavy Metals, Residual Pesticides and Sulfur Dioxide before/after a Decoction - In Prescription consist of Sipjeondaebo-tang -
- Survey on Revision and Complements for the Current Curriculum of Herbology
- The Anticancer Effects and Drug Metabolic Enzyme Change by Intraperitoneal Injection of Agrimonia Pilosa Ledeb
- The Cause of Jeong-Jo’s Death Based on The Annals of the Chosun Dynasty (朝鮮王朝實錄), Seungjeongwon Ilgi (承政院日記)
- A Case Report of Symptomatic Character and Diagnosis of Fibromyalgia
- Oriental Medical Therapy for Sudden Sensorineural Hearing Loss
- more
Recommanded Articles
This website recommended the use the Chrome browser for journal website.